Verex Labs
Executive Summary
ANDA suitability petition for indomethacin constant-release 75 mg tabs was denied by FDA. Verex had filed the petition in January. FDA Office of Drug Standards Div. Director Peter Rheinstein told the firm that investigations are needed to show the safety and efficacy of the proposed product because its "controlled-release mechanism differs significantiy from" the referenced product Indocin SR. Rheinstein explained that "Indocin SR is not a constant release product as referred to in your petition," because if "has kinetic characteristics such that it releases 25 mg of indomethacin initially and then subsequently releases 50 mg more".
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.